# US 2026/0028422 A1 · Anti-MerTK ANTIBODIES AND USES THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0028422 A1
- Document ID: US20260028422A1
- Status: Published application
- Kind: A1
- Application number: 18/997,761
- Filed: 2023-07-28
- Published: 2026-01-29
- Earliest claimed: 2022-07-28
- Assignees: Concept To Medicine Biotech Co., Ltd.; Lepu Biopharma Co., Ltd.
- Applicants: Concept To Medicine Biotech Co., Ltd.; Lepu Biopharma Co., Ltd.
- Inventors: Wenci GONG; Zhijian CAI; Qi WU; Feifei CUI; Lei FANG
- Web page: https://patentgrep.com/patent/US20260028422A1

## CPC

- C07K 16/40: against enzymes
- A61K 40/31: Chimeric antigen receptors [CAR]
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 2239/13: Antibody-based
- A61K 2239/21: Transmembrane domain
- A61K 2239/22: Intracellular domain
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This disclosure provides anti-MerTK antibodies, variants thereof and humanized versions. The newly disclosed antibodies exhibited high affinity to the MerTK protein and can be used to treat cancers, in particular solid tumors.

## Claims

### Claim 1

An antibody or antigen-binding fragment thereof which has specificity to the human Mer proto-oncogene tyrosine-protein kinase (MerTK) protein and comprises a heavy chain variable region (VH) comprising a VH CDR1, a VH CDR2 and a VH CDR3, and a light chain variable region (VL) comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 comprise, respectively, the amino acid sequences of
SEQ ID NO: 25-30;
SEQ ID NO: 59-64;
SEQ ID NO: 65-70;
SEQ ID NO: 31-33, 28-29, 34;
SEQ ID NO: 35-40;
SEQ ID NO: 41-46;
SEQ ID NO: 47-52;
SEQ ID NO: 53-58;
SEQ ID NO: 71, 66, 72, 73, 69, 74;
SEQ ID NO: 65, 75, 67, 76, 69, 77;
SEQ ID NO: 71, 78-79, 73, 69, 74; or
SEQ ID NO: 65-66, 80-81, 69-70.

### Claim 2 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein:
the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 25;
the VH CDR2 comprises an amino acid sequence of SEQ ID NO: 26;
the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 27;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 28;
the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 29; and
the VL CDR3 comprises the amino acid sequence of SEQ ID NO: 30.

### Claim 3 (depends on 2)

The antibody or antigen-binding fragment thereof of claim 2, wherein the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, and 82-87, and the VL comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2 and 89-91.

### Claim 4 (depends on 2)

The antibody or antigen-binding fragment thereof of claim 2, wherein the VH comprises the amino acid sequence of SEQ ID NO: 83, and the VL comprises the amino acid sequence of SEQ ID NO: 90.

### Claim 5 (depends on 2)

The antibody or antigen-binding fragment thereof of claim 2, wherein the VH comprises the amino acid sequence of SEQ ID NO: 83, and the VL comprises the amino acid sequence of SEQ ID NO: 91.

### Claim 6 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein:
the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 59;
the VH CDR2 comprises an amino acid sequence of SEQ ID NO: 60;
the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 61;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 62;
the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 63; and
the VL CDR3 comprises the amino acid sequence of SEQ ID NO: 64.

### Claim 7 (depends on 6)

The antibody or antigen-binding fragment thereof of claim 6, wherein the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 13, 102 and 104, and the VL comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 14 and 106.

### Claim 8 (depends on 6)

The antibody or antigen-binding fragment thereof of claim 6, wherein the VH comprises the amino acid sequence of SEQ ID NO: 102, and the VL comprises the amino acid sequence of SEQ ID NO: 106.

### Claim 9 (depends on 6)

The antibody or antigen-binding fragment thereof of claim 6, wherein the VH comprises the amino acid sequence of SEQ ID NO: 104, and the VL comprises the amino acid sequence of SEQ ID NO: 106.

### Claim 10 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein:
the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 65;
the VH CDR2 comprises an amino acid sequence of SEQ ID NO: 66;
the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 67;
the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 68;
the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 69; and
the VL CDR3 comprises the amino acid sequence of SEQ ID NO: 70.

### Claim 11 (depends on 10)

The antibody or antigen-binding fragment thereof of claim 10, wherein the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 15 and 93-96, and the VL comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 16 and 98-100.

### Claim 12 (depends on 10)

The antibody or antigen-binding fragment thereof of claim 10, wherein the VH comprises the amino acid sequence of SEQ ID NO: 95, and the VL comprises the amino acid sequence of SEQ ID NO: 99.

### Claim 13 (depends on 10)

The antibody or antigen-binding fragment thereof of claim 10, wherein the VH comprises the amino acid sequence of SEQ ID NO: 96, and the VL comprises the amino acid sequence of SEQ ID NO: 99.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

A multispecific antibody comprising an antigen-binding fragment of claim 1 and one or more antibody or antigen-binding fragment having binding specificity to a target antigen that is not MerTK.

### Claim 16 (depends on 1)

A chimeric antigen receptor (CAR) comprising an antigen-binding fragment of claim 1, a transmembrane domain, a costimulatory domain, and a CD3ξ intracellular domain.

### Claim 17 (depends on 1)

One or more polynucleotide(s) encoding the antibody or antigen-binding fragment thereof of claim 1.

### Claim at position 18

18-19. (canceled)

### Claim 20 (depends on 17)

A cell comprising the polynucleotide(s) of claim 17.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

A method of treating cancer or an inflammatory condition in a patient in need thereof, comprising administering to the patient an effective amount of the antibody or antigen-binding fragment thereof of claim 1.

### Claim 23

(canceled)

### Claim 24 (depends on 22)

The method of claim 22, wherein the cancer is a solid tumor.

### Claim 25

(canceled)

### Claim 26 (depends on 22)

The method of claim 22, wherein the inflammatory condition is selected from the group consisting of Alzheimer's disease, Addison's disease, atherosclerosis, ankylosing spondylitis, arthritis, osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis (PA), ankylosing spondylitis, asthma, atherosclerosis, chronic obstructive pulmonary disease (COPD), Crohn's disease, colitis, dermatitis, diverticulitis, fibromyalgia, hepatitis, irritable bowel syndrome (IBS), systemic lupus erythematous (SLE), nephritis, Parkinson's disease (PD), vasculitis, and ulcerative colitis.
